FDA OKs Aclaris' Eskata for seborrheic keratoses

|About: Aclaris Therapeutics (ACRS)|By:, SA News Editor

The FDA approves Aclaris Therapeutics' (NASDAQ:ACRS) ESKATA (hydrogen peroxide) topical solution, 40% for the treatment of raised seborrheic keratoses (non-cancerous skin growths).

The product is designed for in-office application by a healthcare provider via a pen-like applicator. Market launch will commence in the spring of 2018.

Management will host a conference call this morning at 8:00 am ET to discuss the approval.

Update: Shares are up 10% premarket on light volume.

Update: On May 7, the company announced the U.S. launch.

Subscribe for full text news in your inbox